Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Neurofibromatosis 1 3Neurofibromatoses 3Neurofibroma, Plexiform 2Neurofibroma 2Melanoma 2Glioma 2Colorectal Neoplasms 2Breast Neoplasms 2Vascular Malformations 1Solid Tumor, Adult 1Skin Diseases, Vascular 1Primary Malignant Peripheral Nerve Sheath Tumors 1Oligodendroglioma 1Neurocytoma 1Neoplasms, Neuroepithelial 1NF1 1Multiple Myeloma 1Lymphatic Abnormalities 1Lymphangioma, Cystic 1Lymphangioma 1Liposarcoma, Myxoid 1Liposarcoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1KRAS Mutant Non-Small Cell Lung Cancer 1Glioblastoma 1Ganglioneuroma 1Ganglioglioma 1Colonic Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Fluorouracil 219Leucovorin 202Oxaliplatin 192Irinotecan 150Bevacizumab 110Capecitabine 94Cetuximab 90Folfox protocol 54Chemotherapy, Adjuvant 36Panitumumab 30Colonoscopy 30pembrolizumab 23Drug Therapy 23Nivolumab 22Magnetic Resonance Spectroscopy 22Gemcitabine 21Blood Specimen Collection 20Radiotherapy 19Floxuridine 19Biopsy 19Neoadjuvant Therapy 18Laparoscopy 18IFL protocol 18Early Intervention, Educational 18Celecoxib 18Surveys and Questionnaires 17Surgical Procedures, Operative 16Immunohistochemistry 16Exercise 16trifluridine tipiracil drug combination 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Colonic Neoplasms × mirdametinib × Clear all
NCT00147550 2013-09-13

MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma.

Pfizer

Phase 1/2 Terminated
79 enrolled
BreastDermatologicGastrointestinal

Breast Neoplasms, Colonic Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡